8月20日，远大医药(00512)盘中上涨3.14%，截至13:52，报9.2元/股，成交3.01亿元。
远大医药集团有限公司是一家加科技创新型国际化医药企业，主要业务包括制药科技、核药抗肿瘤诊疗及心脑血管精准介入诊疗科技，以及生物科技。该公司拥有全球超过一万名员工，30多家境内外附属公司，5个技术平台和8个研发中心，超过200个医保目录产品和16个销售额超过一亿的产品，业务覆盖多个医疗领域，近年来也在全球范围内布局创新药械产品，并与多家世界领先医药企业、大学和科研机构建立合作关系。
截至2025年中报，远大医药营业总收入55.7亿元、净利润10.66亿元。
8月19日，2025财年中报归属股东应占溢利11.69亿港元，同比下降24.96%，基本每股收益0.3338港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.